Pulmonx Corporation LUNG

Company Overview

Pulmonx Corporation is a U.S.-based medical technology company focused on minimally invasive treatments for severe lung disease, primarily emphysema associated with chronic obstructive pulmonary disease (COPD). The company operates within the interventional pulmonology and respiratory medical device industries and is best known for its Zephyr Endobronchial Valve system, a bronchoscopic treatment designed to reduce hyperinflation in patients with severe emphysema. Pulmonx generates most of its revenue from the sale of its valve systems, related catheter products, and procedural support services used by hospitals and specialized pulmonary care centers.

The company’s core customer base includes pulmonologists, thoracic specialists, and healthcare systems treating advanced COPD patients. Pulmonx has positioned itself as a leader in bronchoscopic lung volume reduction (BLVR), supported by clinical trial data, regulatory approvals in multiple regions, and physician training infrastructure. Founded in 1995, the company evolved from an early-stage pulmonary device developer into a publicly traded respiratory intervention company following years of clinical development, commercialization expansion, and regulatory milestones, including U.S. FDA approval for the Zephyr Valve in 2018.

Business Operations

Pulmonx primarily operates through a single medical technology business centered on the commercialization of the Zephyr Valve System and associated diagnostic platforms. Revenue is generated through sales of implantable valves, procedure-related products, and the company’s Chartis Pulmonary Assessment System, which assists physicians in identifying suitable candidates for treatment. The company’s business model relies heavily on hospital adoption, physician education, reimbursement expansion, and clinical evidence supporting patient outcomes.

The company conducts operations across the United States, Europe, and selected international markets through direct sales teams and distributor relationships. Pulmonx maintains intellectual property related to bronchoscopic lung volume reduction technologies and clinical workflow tools. Strategic relationships with healthcare institutions, pulmonary centers of excellence, and reimbursement stakeholders are important components of its commercialization strategy. Public filings identify wholly owned operating subsidiaries involved in international commercial activities, though detailed operational segmentation remains limited because the company reports as a single operating segment.

Strategic Position & Investments

Pulmonx’s strategic direction centers on expanding physician adoption of minimally invasive emphysema treatments and increasing global penetration of bronchoscopic lung volume reduction procedures. The company has invested significantly in clinical studies, physician training programs, patient awareness initiatives, and reimbursement support infrastructure to strengthen adoption in both established and emerging markets. Management has consistently emphasized increasing treatment accessibility for severe COPD patients who are not ideal candidates for invasive lung surgery.

The company continues to invest in product innovation, data generation, and market expansion initiatives tied to interventional pulmonology. Pulmonx has also pursued selective technology and intellectual property development related to pulmonary diagnostics and procedural optimization. While the company’s primary focus remains emphysema treatment, its broader strategic positioning aligns with the growing demand for minimally invasive respiratory therapies driven by aging populations and increasing COPD prevalence globally.

Geographic Footprint

Pulmonx is headquartered in Redwood City, California, and maintains commercial operations across North America, Europe, and selected markets in Asia-Pacific and other international regions. The United States represents the company’s largest market by revenue, supported by FDA approval, reimbursement coverage expansion, and increasing hospital adoption of bronchoscopic emphysema treatments.

Internationally, Pulmonx has established a meaningful presence in countries including Germany, France, United Kingdom, and other European markets where minimally invasive lung volume reduction procedures have gained clinical acceptance. The company supports international growth through direct commercial infrastructure and third-party distribution networks, with strategic emphasis on regions that demonstrate favorable reimbursement environments and advanced pulmonary care capabilities.

Leadership & Governance

Pulmonx is led by an executive team with experience in medical devices, commercialization, and respiratory healthcare technologies. Corporate governance is overseen by a board of directors composed of healthcare, medical technology, and financial industry leaders. Leadership strategy has consistently focused on evidence-based commercialization, physician engagement, and expanding access to minimally invasive emphysema care through clinical validation and reimbursement development.

Key executives include:

• Steve Williamson – President and Chief Executive Officer
• Glenda Hector – Chief Financial Officer
• Patricia Wirth – Chief Commercial Officer
• Glen French – Chief Medical Officer
• Fumiko Chino – Chief Human Resources Officer

The company’s leadership has emphasized long-term growth through clinical differentiation, operational scaling, and expansion of the interventional pulmonology ecosystem surrounding the Zephyr Valve System. Information regarding executive leadership and governance structure has been consistently disclosed through SEC filings, annual reports, and investor communications.